Prostate CA Clinical Trials in Nanjing, Jiangsu
28 recruitingNanjing, Jiangsu, China
Showing 1–20 of 28 trials
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled286 locationsNCT06925737
Recruiting
Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Prostate Cancer
Novartis Pharmaceuticals940 enrolled70 locationsNCT06855277
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Advanced Metastatic Castration-resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.84 enrolled22 locationsNCT06609005
Recruiting
Phase 2Phase 3
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Prostate Cancer
Novartis Pharmaceuticals443 enrolled81 locationsNCT06780670
Recruiting
Phase 2
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Zenith Epigenetics200 enrolled31 locationsNCT04986423
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled282 locationsNCT06136624
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
Prostate CancerDiffusion MRI
First Affiliated Hospital of Zhejiang University2,000 enrolled6 locationsNCT07249281
Recruiting
Phase 2Phase 3
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
Prostate CA
baotai Liang83 enrolled1 locationNCT06861192
Recruiting
Phase 2
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Prostate Cancer
baotai Liang93 enrolled1 locationNCT07163910
Recruiting
Phase 2
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
Prostate Cancer Metastatic Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School144 enrolled1 locationNCT06992232
Recruiting
Phase 3
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Metastatic Prostate CancerTherapy, Directly Observed
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT06350825
Recruiting
Phase 2
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Prostate CancerBiochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School102 enrolled2 locationsNCT06305832
Recruiting
Phase 3
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
Metastatic Prostate CancerIntermitent Anti-androgen Therapy
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT06177015
Recruiting
Phase 3
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Chemotherapy EffectMetastatic Prostate CancerHormone Sensitive Prostate Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05983783
Recruiting
Phase 2
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Prostate CancerBiochemical Recurrence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School96 enrolled2 locationsNCT05753566
Recruiting
Phase 2
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Neoadjuvant TherapyHigh-risk Prostate CancerLocally Advanced Prostate Cancer+1 more
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School900 enrolled1 locationNCT05406999